GlassScriptPhysician profile
Tyrone T Lee
NPI 1235108697
$3,684.46
in general payments reported to CMS, 2019-2025
26 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $139 · 2021: $789 · 2022: $656 · 2023: $721 · 2024: $637 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.08 |
| Education | $290.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $957.55 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Mallinckrodt Hospital Products INC. | $577.05 | 2020-2025 | Acthar |
| Electromed, INC. | $420.43 | 2021-2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $311.51 | 2021-2024 | Dupixent |
| Genzyme Corporation | $289.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.67 | 2019-2025 | Spiriva Respimat, Jascayd, Ofev |
| Philips North America LLC | $104.75 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| United Therapeutics Corporation | $76.58 | 2022-2024 | Tyvaso |
| Mylan Specialty L.P. | $66.13 | 2021-2023 | Yupelri |
| Pfizer INC. | $60.11 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $59.94 | 2021-2023 | Uptravi, Opsumit |
| Baxter Healthcare | $45.54 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Hikma Pharmaceuticals USA | $42.00 | 2023-2024 | Ryaltris |
| Harmony Biosciences LLC | $41.89 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $39.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.14 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $32.84 | 2022 | |
| Vapotherm INC | $27.07 | 2019 | |
| Circassia INC. | $23.65 | 2019 | |
| Csl Behring | $16.82 | 2019 | |
| Tactile Systems Technology INC | $15.49 | 2022 | |
| Lilly USA, LLC | $15.18 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $14.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.68 | 2025 | |
| Glaxosmithkline, LLC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyrone Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.